Загрузка...
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
Delayed-release dimethyl fumarate (DMF), also known as gastroresistant DMF, is the most recently approved oral disease-modifying treatment (DMT) for relapsing multiple sclerosis. Two randomized clinical trials (Determination of the Efficacy and Safety of Oral Fumarate in Relapsing–Remitting MS [DEFI...
Сохранить в:
| Опубликовано в: : | Ther Clin Risk Manag |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4780395/ https://ncbi.nlm.nih.gov/pubmed/27042079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S85099 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|